Preclinical Alzheimer’s disease (AD) clinical trials screen cognitively unimpaired older adults for biomarker criteria and disclose their results. We examined whether participants in the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease Study with “elevated” and “not elevated” amyloid differed in scores on the “Views and Perceptions of Amyloid Imaging” questionnaire. We hypothesized that, prior to disclosure, those with elevated amyloid would score higher than those with not elevated amyloid. We also quantified how responses changed after result disclosure.

中文翻译：

---

认知未受损的老年人接受淀粉样蛋白成像的原因


临床前阿尔茨海默病 (AD) 临床试验根据生物标志物标准筛选认知未受损的老年人，并披露其结果。我们检查了无症状阿尔茨海默病抗淀粉样蛋白治疗研究中淀粉样蛋白“升高”和“不升高”的参与者在“淀粉样蛋白成像的看法和看法”问卷中的得分是否存在差异。我们假设，在披露之前，淀粉样蛋白升高的人的得分会高于淀粉样蛋白未升高的人。我们还量化了结果披露后反应如何变化。